PK / PD study of the oral FXa inhibitor edoxaban in patients with non-valvular atrial fibrillation who developed acute heart failure
Latest Information Update: 07 Apr 2021
At a glance
- Drugs Edoxaban (Primary)
- Indications Atrial fibrillation; Heart failure
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 07 Apr 2021 New trial record
- 30 Mar 2021 Results assessing pharmacokinetics and pharmacodynamics profiles and safety of edoxaban in patients with non-valvular atrial fibrillation and acute heart failure, published in the Clinical Pharmacokinetics.